Preventative policies in transfusion associated graft versus host disease in the treatment of cancer.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 7726615.
- Also identified by PMC identifier 1030093.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Experience of transfusion associated graft versus host disease (TA-GvHD) and current preventative policy in 22 UK children's cancer centres was established by questionnaire. Cellular blood products were irradiated in all centres during bone marrow transplantation, but there was no consensus for children receiving standard chemotherapy. Irradiation dose varied from 1500-5000 cGy and was below 2500 cGy in 12 units. Five cases of TA-GvHD were identified; all five children died.
Medical subject headings
- Graft vs Host Disease
- Transfusion Reaction